LGD1069: Filed IND to start Phase I/IIa trials

Ligand Pharmaceuticals Inc. (LGNDA), San Diego Product: LGD1069 topical formulation, which selectively activates the X subclass of retinoid receptors to induce apoptosis in cancerous cells Indication...